| Primary information |
|---|
| ThPP ID | Th1192 |
| Therapeutic Peptide/Protein Name | Ustekinumab |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | 14690 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | CNTO 1275 is the experimental name for the human immunosuppressive drug ustekinumab developed by the biotechnology company Centocor. It is a laboratory manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23. |
| Indication/Disease | For treatment in psoriasis and psoriatic disorders. |
| Pharmacodynamics | NA |
| Mechanism of Action | Similar to the immunosuppressive function of Etanercept (Enbrel), CNTO 1275 is designed to interfere with the triggering of the body's inflamatory response through the suppression of certain cytokines. Specifically, CNTO 1275 blocks interleukin IL-12 and IL-23 (via the p40 subunit of IL-12 and IL-23) which help activate certain T-cells. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | Deramtologic agent, Immunosuppressive agent, antineoplastic agent |
| Patents Number | |
| Date of Issue | |
| Date of Expiry | |
| Drug Interaction | Belimumab, Denosumab, Infliximab, Leflunomide, Natalizumab, Pimecrolimus, Roflumilast, Sipuleucel-T, Tacrolimus, Tofacitinib, Trastuzumab |
| Target | Interleukin-12 subunit beta |
| Information of corresponding available drug in the market |
|---|
| Brand Name | Stelara |
| Company | Janssen Biotech, Inc. |
| Brand Discription | STELARA is a human IgG1κ monoclonal antibody against the p40 subunit of the IL-12 and IL23 cytokines. Using DNA recombinant technology, STELARA® is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA® is comprised of 1326 amino acids |
| Prescribed for | Psoriasis (Ps) and Psoriatic Arthritis (PsA) |
| Chemical Name | NA |
| Formulation | Each 45 mg ustekinumab prefilled syringe also contains: L-histidine and L-histidine monohydrochloride monohydrate (0.5 mg), Polysorbate 80 (0.02 mg), and sucrose (38 mg) to fill to a final volume of 0.5 mL. |
| Physcial Appearnce | solution fro injection |
| Route of Administration | Subcutaneous |
| Recommended Dosage | In case of psoriasis, for patients weighing ≤ 100 kg (220 lbs), the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. In case of Psoriatic Arthritis ecommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. |
| Contraindication | NA |
| Side Effects | Adverse reactions that occurred at rates less than 1% in the controlled period of Ps STUDIES 1 and 2 through week 12 included: cellulitis, herpes zoster, diverticulitis and certain injection site reaction |
| Useful Link | http://www.rxlist.com/stelara-drug.htm |
| PubMed ID | 25633241, 24997741, 19222517, 26432476, 26607958, 25284845, 22531442, 22171583, 22168335 |
| 3-D Structure | N.A. |